These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 37470319)

  • 1. The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
    Akbulut F; Pazir Y; Esmeray A; Erbin A; Ozgor F; Sarilar O
    Urologia; 2023 Nov; 90(4):631-635. PubMed ID: 37470319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
    Pazir Y; Esmeray A; Caglar U; Erbin A; Ozgor F; Sarilar O; Akbulut F
    Int Urol Nephrol; 2024 Mar; 56(3):957-963. PubMed ID: 37880493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
    Guerrero-Ramos F; González-Padilla DA; González-Díaz A; de la Rosa-Kehrmann F; Rodríguez-Antolín A; Inman BA; Villacampa-Aubá F
    World J Urol; 2022 Apr; 40(4):999-1004. PubMed ID: 35037963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center.
    Kastner L; Rieger C; Pfister D; Schmautz M; Storz E; Heidenreich A
    Urol Oncol; 2024 Aug; 42(8):245.e19-245.e26. PubMed ID: 38653592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy and Safety of Hyperthermia Intravesical Chemotherapy in the Treatment of Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis.
    Duan H; Deng Z; Zou J; Zhang G; Zou X; Xie T
    Urol Int; 2024; 108(4):322-333. PubMed ID: 38508149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure.
    Pignot G; Baboudjian M; Lebacle C; Chamouni A; Lechevallier E; Irani J; Tillou X; Waeckel T; Monges A; Doisy L; Walz J; Gravis G; Mourey E; Duperron C; Masson-Lecomte A
    World J Urol; 2023 Nov; 41(11):3195-3203. PubMed ID: 36811732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M
    Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
    Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
    Grimberg DC; Dudinec J; Shah A; Inman BA
    Urol Oncol; 2021 Aug; 39(8):498.e13-498.e20. PubMed ID: 33485761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
    Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients.
    Thomsen JA; Nielsen Dominiak H; Lindgren MS; Jensen JB
    Scand J Urol; 2021 Aug; 55(4):281-286. PubMed ID: 34124993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.
    Magalhães JC; Sousa M; Basto R; Fraga T; Gomes I; Fernandes C; Mariano M; Paulo J; Madeira P; Sousa G
    Cureus; 2023 Sep; 15(9):e45672. PubMed ID: 37745737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
    Massari M; O'Malley P; Benidir T; Su LM; Gao H; Crispen PL
    Urol Oncol; 2024 Sep; 42(9):289.e7-289.e12. PubMed ID: 38802293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy.
    Doisy L; Cimier A; Adypagavane A; Walz J; Marquette T; Maubon T; Rybikowski S; Fakhfakh S; Loverde K; Mottet N; Irani J; Lechevallier E; Rossi D; Gravis G; Pignot G
    Int J Hyperthermia; 2021; 38(1):1633-1638. PubMed ID: 34775896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermal intravesical chemotherapy in adjuvant treatment of high risk non-muscle invasive bladder cancer.
    Efiloğlu Ö; Bayrak Ö; Turan T; Kazan HÖ; Çulpan M; Çakıcı MÇ; Erturhan S; Yıldırım A
    Arch Esp Urol; 2021 Nov; 74(9):875-882. PubMed ID: 34726624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study.
    Brisuda A; Horňák J; Žemličková B; Háček J; Babjuk M
    Int Urol Nephrol; 2024 Jul; 56(7):2243-2250. PubMed ID: 38329573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.
    Angulo JC; Álvarez-Ossorio JL; Domínguez-Escrig JL; Moyano JL; Sousa A; Fernández JM; Gómez-Veiga F; Unda M; Carballido J; Carrero V; Fernandez-Aparicio T; García de Jalón Á; Solsona E; Inman B; Palou J
    Eur Urol Oncol; 2023 Feb; 6(1):58-66. PubMed ID: 36435738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
    Tan WS; Prendergast A; Ackerman C; Yogeswaran Y; Cresswell J; Mariappan P; Phull J; Hunter-Campbell P; Lazarowicz H; Mishra V; Rane A; Davies M; Warburton H; Cooke P; Mostafid H; Wilby D; Mills R; Issa R; Kelly JD
    Eur Urol; 2023 Jun; 83(6):497-504. PubMed ID: 35999119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.